NanoPalm
Startups
Information
NanoPalm is a DeepTech company revolutionizing in-vivo gene therapies for genetic diseases with an advanced Lipid Nanoparticle (LNP) manufacturing process to create stable LNPs that can self-target specific organs and cells without the downsides of current LNP-based therapies.
On top of our growing megalibrary of nanoparticle experiment data, NanoPalm has built Ensalix, an AI-platform that predicts the novel LNP cures to target a specific cell or organ with mRNA. Ensalix uses computer vision, machine learning and artificial intelligence to predict optimal nanomedicines.
Ensalix has already predicted several promising cures, which are now in development. Beyond our own pipeline, we’re beginning co-development discussions for new indications using Ensalix and our next generation manufacturing process.
